Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Synvista Therapeutics, Inc |
---|---|
Information provided by: | Synvista Therapeutics, Inc |
ClinicalTrials.gov Identifier: | NCT00045994 |
The purpose of this study is to evaluate the safety and efficacy of ALT-711 in the treatment of isolated systolic hypertension in a formal study in patients with left ventricular hypertrophy. Eligible patients will be randomized to double-blind treatment once daily for 6 months with oral ALT-711 (210 mg) or placebo.
Condition | Intervention | Phase |
---|---|---|
Hypertension Hypertrophy, Left Ventricular |
Drug: ALT-711 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The SILVER Study |
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Study ID Numbers: | ALT-711-0107-Silver |
Study First Received: | September 17, 2002 |
Last Updated: | August 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00045994 |
Health Authority: | United States: Food and Drug Administration |
cardiovascular aged antihypertensive agents/therapeutic use hypertension/*drug therapy blood pressure |
Pathological Conditions, Anatomical Hypertrophy, Left Ventricular Hypertrophy Heart Diseases |
Vascular Diseases Cardiomegaly Hypertension |
Cardiovascular Diseases |